Please login to the form below

Not currently logged in
Email:
Password:

AZ's Lisa Anson elected president of ABPI

She takes up the lead role from April 2017

AZ Lisa AnsonThe Association of the British Pharmaceutical Industry has elected Lisa Anson to serve as its president from the end of April next year.

Anson joined the ABPI board in 2012 and has since overseen a number of schemes for the association, including the implementation of the Pharmaceutical Pricing Regulation Scheme.

Currently serving as president of AstraZeneca UK and Ireland, Anson has held several senior management positions at the firm, including vice president of emerging brands.

She brings further pharmaceutical management experience from California-based Salick Health Care, where she was vice president of strategy, and management consultancy expertise from KPMG.

Mike Thompson, the ABPI's chief executive said: “The unanimous decision by the ABPI board to elect Lisa Anson as president shows the esteem in which she is held.

“As a high profile president of AstraZeneca UK and Ireland her knowledge and experience will be valuable as we head into what is arguably the UK pharmaceutical industry's most challenging era to date.

“Lisa will play a leading role as we negotiate the future of our industry outside the European Union and as we work with government to build an industrial strategy with life-sciences at its heart.

“Speaking on behalf of the board and all staff at the ABPI, we very much look forward to working with Lisa.”

14th December 2016

From: Healthcare

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...